Equity research firm Jefferies initiated coverage on BeiGene (NASDAQ: BGNE ) with a "buy" rating and a price target of $287. BeiGene is an oncology company with a strong presence in China, and Jefferies sees it as an R&D "powerhouse" with a rich portfolio of treatments for tumors.
Jefferies noted that BeiGene has a unique business model combining advantages of its strong China presence and global commercial network to innovate with speed and quality at low cost. Jefferies analysts also noted the best-in-class potential of BTK inhibitor BRUKINSA and tislelizumab's leading position in the PD-1 market in China.
The analysts explained, “BGNE is an oncology-focused China-originated company featured by its R&D powerhouse and global commercial networks, which are showcased by best-in-class BTK inhibitor BRUKINSA poised to excel in $10B+ global market and tislelizumab's leading position in a competitive PD-1 market in China. A deep and broad pipeline will sustain long-term growth, and strategic partners Novartis and Amgen should further extend BGNE's global reach.”
BeiGene has a market cap of around $20 billion, and the stock trades at just over $190 per share. At least 15 Wall Street analysts have a buy or buy-equivalent rating on the stock, but shares are down by over 10% this year.
Add Chart to Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
- Enrich the conversation
- Stay focused and on track. Only post material that’s relevant to the topic being discussed.
- Be respectful. Even negative opinions can be framed positively and diplomatically.
- Use standard writing style. Include punctuation and upper and lower cases.
- NOTE: Spam and/or promotional messages and links within a comment will be removed
- Avoid profanity, slander or personal attacks directed at an author or another user.
- Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
- Only English comments will be allowed.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.